New drug combo aims to keep HER2+ esophageal cancer from coming back
NCT ID NCT05480384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with HER2-positive esophageal or gastroesophageal junction cancer who have already completed chemoradiation and surgery. The goal is to see if adding a year of treatment with trastuzumab deruxtecan (Enhertu) plus nivolumab is safe and helps prevent the cancer from returning. Only one participant was enrolled, and the study focuses on side effects and how long people stay cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Weill Cornell Medicine/New York-Presbyterian
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can 3D motion capture reveal hidden breathing problems after esophageal cancer surgery?
- Can Real-World data improve esophageal cancer care in africa?
- Targeted Antibody-Drug combo aims to tackle High-Risk bladder cancer
- Stent showdown: which esophageal prosthesis best restores swallowing in advanced cancer?
- Personalized radiation pulses could boost esophageal cancer treatment